Randomized trials to optimize treatment of multidrug-resistant tuberculosis
2007

Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis

publication Evidence: high

Author Information

Author(s): Carole D. Mitnick, Kenneth G. Castro, Mark Harrington, Leonard V. Sacks, William Burman

Primary Institution: Harvard Medical School

Hypothesis

The time is now right for randomized trials of MDR-TB.

Conclusion

Randomized trials are essential to identify safe and effective regimens for treating multidrug-resistant tuberculosis.

Supporting Evidence

  • Drug-resistant tuberculosis accounts for 10% of new TB cases annually.
  • Current MDR-TB treatment outcomes are suboptimal, with many patients dying during treatment.
  • New drug classes for MDR-TB are under development and need evaluation.

Takeaway

We need to test new treatments for a serious type of tuberculosis that is hard to cure, so we can help more people get better.

Methodology

The article discusses the need for randomized clinical trials to evaluate new drug regimens for MDR-TB.

Limitations

Current treatment regimens for MDR-TB are long, toxic, and often unsuccessful.

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040292

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication